B cell receptor specific for Plasmodium falciparum peptide epitopes (BCR-Pf)

The B cell receptor (BCR) specific for Plasmodium falciparum peptide epitopes is a transmembrane protein complex on B lymphocytes that plays a pivotal role in the adaptive immune response against malaria (Tan et al., 2018, Nature Medicine). These receptors recognize specific antigenic determinants on the surface of Plasmodium falciparum, such as the circumsporozoite protein (CSP) or merozoite surface proteins (MSP) (NCBI, 2023). Upon binding to its cognate peptide epitope, the BCR triggers signaling cascades that result in B cell proliferation and the production of protective antibodies (UniProt, 2024). In clinical practice, these receptors are the primary targets of malaria vaccines like RTS,S/AS01 and R21/Matrix-M, which aim to induce specific BCR-mediated immunity (WHO, 2023). Additionally, monoclonal antibodies such as CIS43 and L9LS, which are derived from these BCRs, are being evaluated for passive immunization (Gaudinski et al., 2021, NEJM). The study of these receptors is essential for overcoming the parasite's immune evasion strategies, including antigenic variation (PubMed, 2022). Understanding the structural basis of these interactions allows for the design of more effective immunogens in reverse vaccinology approaches (Nature, 2019).

Other names

Malaria-specific B cell receptorPlasmodium-specific BCRAnti-Plasmodium B cell receptorPf-specific BCR

Vaccines act as ligands to stimulate BCR-mediated B cell activation and memory formation; monoclonal antibodies act as exogenous versions of these receptors to neutralize the parasite.